Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 7
1967 5
1968 9
1969 4
1970 7
1971 9
1972 8
1973 8
1974 7
1975 5
1976 15
1977 22
1978 9
1979 15
1980 6
1981 8
1982 13
1983 11
1984 9
1985 17
1986 12
1987 8
1988 14
1989 12
1990 11
1991 12
1992 10
1993 7
1994 12
1995 3
1996 7
1997 6
1998 6
1999 9
2000 4
2001 8
2002 12
2003 3
2004 2
2005 8
2006 6
2007 10
2008 11
2009 13
2010 8
2011 8
2012 16
2013 14
2014 5
2015 13
2016 14
2017 12
2018 19
2019 7
2020 12
2021 20
2022 31
2023 25
2024 16
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

609 results

Results by year

Filters applied: . Clear all
Page 1
Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R, Simeoli C, Di Paola N, Colao A. Pivonello R, et al. Pituitary. 2022 Oct;25(5):726-732. doi: 10.1007/s11102-022-01262-8. Epub 2022 Aug 29. Pituitary. 2022. PMID: 36036308 Free PMC article. Review.
Drug design strategies for Cushing's syndrome.
Usanov SA, Kliuchenovich AV, Strushkevich NV. Usanov SA, et al. Expert Opin Drug Discov. 2019 Feb;14(2):143-151. doi: 10.1080/17460441.2019.1559146. Epub 2018 Dec 20. Expert Opin Drug Discov. 2019. PMID: 30572739 Review.
Glucocorticoid receptor blockers.
Molitch ME. Molitch ME. Pituitary. 2022 Oct;25(5):733-736. doi: 10.1007/s11102-022-01227-x. Epub 2022 May 4. Pituitary. 2022. PMID: 35507245 Review.
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, Drui D, Lasolle H, Vieira-Pinto O, Salenave S, François M, Puerto M, Boullay HD, Mayer A, Rod A, Laurent C, Chanson P, Reznik Y, Castinetti F, Chabre O, Baudin E, Raverot G, Tabarin A, Young J. Dormoy A, et al. J Clin Endocrinol Metab. 2023 May 17;108(6):1475-1487. doi: 10.1210/clinem/dgac691. J Clin Endocrinol Metab. 2023. PMID: 36470583 Free PMC article.
Osilodrostat: First Approval.
Duggan S. Duggan S. Drugs. 2020 Apr;80(5):495-500. doi: 10.1007/s40265-020-01277-0. Drugs. 2020. PMID: 32141023 Review.
Systemic therapy of Cushing's syndrome.
Eckstein N, Haas B, Hass MD, Pfeifer V. Eckstein N, et al. Orphanet J Rare Dis. 2014 Aug 5;9:122. doi: 10.1186/s13023-014-0122-8. Orphanet J Rare Dis. 2014. PMID: 25091295 Free PMC article. Review.
609 results